SBC Medical Group (NASDAQ:SBC) CEO Yoshiyuki Aikawa Sells 3,100,000 Shares
by Scott Moore · The Cerbat GemSBC Medical Group Holdings Incorporated (NASDAQ:SBC – Get Free Report) CEO Yoshiyuki Aikawa sold 3,100,000 shares of the business’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $3.02, for a total value of $9,362,000.00. Following the sale, the chief executive officer owned 79,304,460 shares of the company’s stock, valued at approximately $239,499,469.20. This represents a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Yoshiyuki Aikawa also recently made the following trade(s):
- On Friday, March 6th, Yoshiyuki Aikawa sold 4,422,900 shares of SBC Medical Group stock. The shares were sold at an average price of $2.12, for a total value of $9,376,548.00.
SBC Medical Group Price Performance
Shares of SBC Medical Group stock remained flat at $3.40 during trading hours on Thursday. The company’s stock had a trading volume of 140,319 shares, compared to its average volume of 117,629. The business’s 50 day moving average is $4.01 and its 200 day moving average is $4.02. The company has a market capitalization of $348.77 million, a price-to-earnings ratio of 6.94 and a beta of 0.99. SBC Medical Group Holdings Incorporated has a 1-year low of $2.97 and a 1-year high of $5.75. The company has a quick ratio of 3.74, a current ratio of 3.78 and a debt-to-equity ratio of 0.13.
SBC Medical Group (NASDAQ:SBC – Get Free Report) last released its quarterly earnings results on Friday, March 27th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. The business had revenue of $39.57 million during the quarter, compared to the consensus estimate of $45.19 million. SBC Medical Group had a return on equity of 20.76% and a net margin of 29.37%. Sell-side analysts anticipate that SBC Medical Group Holdings Incorporated will post 0.47 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d+)” rating on shares of SBC Medical Group in a research note on Friday, March 27th. BTIG Research started coverage on SBC Medical Group in a research note on Friday, March 6th. They set a “buy” rating and a $8.00 price target for the company. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SBC Medical Group currently has an average rating of “Hold” and a consensus price target of $8.50.
Get Our Latest Stock Analysis on SBC
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its stake in shares of SBC Medical Group by 195.1% during the 4th quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock valued at $54,000 after acquiring an additional 8,348 shares during the period. Russell Investments Group Ltd. grew its stake in shares of SBC Medical Group by 292.0% during the 4th quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock valued at $51,000 after acquiring an additional 8,771 shares during the period. Barclays PLC grew its stake in shares of SBC Medical Group by 123.7% during the 4th quarter. Barclays PLC now owns 17,779 shares of the company’s stock valued at $77,000 after acquiring an additional 9,831 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of SBC Medical Group during the 4th quarter valued at approximately $49,000. Finally, Nuveen LLC bought a new position in shares of SBC Medical Group during the 4th quarter valued at approximately $53,000. 60.82% of the stock is currently owned by institutional investors.
About SBC Medical Group
SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.
The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.